Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$20.56-0.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SNDX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue expanding Revuforj net revenue and prescriptions with ongoing clinical trials and new data presentations.
Stated as a priority in 2 of last 2 quarters. Revuforj net revenue grew from $48.9 million in 2026-Q1 to $54.7 million in 2026-Q2, a 91% year-over-year increase in 2Q26. Prescription volume also increased significantly. Management highlights multiple ongoing pivotal trials and upcoming data presentations supporting continued growth. The trajectory is delivering consistent commercial expansion and clinical development progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Achieved $54.7 million in Revuforj net revenue in 2Q26, a 91% increase over 2Q25 and 12% over 1Q26; ~1,500 prescriptions, 121% increase over 2Q25.”
“Achieved $48.9 million in Revuforj net revenue in 1Q26, a 144% increase over 1Q25 and 11% over 4Q25; total prescriptions increased ~160% over 1Q25.”
Grow Niktimvo net revenue and collaboration revenue with ongoing Phase 2 and Phase 3 trials and expected topline data.
Stated as a priority in 2 of last 2 quarters. Niktimvo net revenue increased from $55.1 million in 2026-Q1 to $60.3 million in 2026-Q2, a 67% year-over-year increase in 2Q26. Collaboration revenue also grew accordingly. Management highlights ongoing Phase 2 and Phase 3 trials in chronic GVHD and IPF with topline data expected in late 2026 and early 2028. The trajectory shows continued commercial growth and clinical progress.
“Achieved $60.3 million in Niktimvo net revenue in 2Q26, a 67% increase over 2Q25; collaboration revenue was $18.1 million.”
“Achieved $55.1 million in Niktimvo net revenue in 1Q26, significant growth from $13.6 million in 1Q25; collaboration revenue was $15.9 million.”
Develop internally and externally sourced pipeline assets including SNDX-62122 for myelofibrosis and SNDX-4321 for EGFR-mutated NSCLC.
Newly stated in 2026-07. Management announced the addition of SNDX-4321, an allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis, with IND submissions and Phase 1 trials planned for 2027. This represents a strategic pipeline expansion leveraging internal and external innovation. No financial metrics yet available; progress is early-stage.
Maintain total research and development plus selling, general and administrative expenses near $400 million for 2026.
Stated as a priority in 4 of last 4 quarters. Management consistently expects total research and development plus selling, general and administrative expenses to be approximately $400 million for 2026, excluding $50 million in non-cash stock compensation. This follows guidance of $380-$385 million for 2025. The trajectory shows stable expense management aligned with stated targets.
“Company continues to expect total R&D plus SG&A expenses to be approximately $400 million for 2026, excluding $50 million non-cash stock compensation.”
“Company expects total R&D plus SG&A expenses to be approximately $400 million for 2026, excluding $50 million non-cash stock compensation.”
“Company expects total R&D plus SG&A expenses to be approximately $400 million for 2026.”
“Company expects total R&D plus SG&A expenses to be $380 to $385 million for 2025.”
Complete private placement of $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031.
Newly stated in 2026-06. Management announced a private placement of $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031, expected to close June 10, 2026. This capital raise aims to support general corporate purposes including R&D and commercialization. The event is recent with no subsequent financial impact reported yet.
Over the trailing year it converted 0.99x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.